COMPANY NEWS


Biocon Ltd
BSE Code 532523 ISIN Demat INE376G01013 Book Value (₹) 90.88 NSE Symbol BIOCON Div & Yield % 0.16 Market Cap ( Cr.) 36,720.35 P/E * 339.83 EPS * 0.9 Face Value (₹) 5
* Profit to Earning Ratio
* Earning Per Share
Biocon receives Complete Response Letter for Biologics License Application Back
(09 Feb 2024)
Biocon announced that the U.S. Food and Drug Administration (US FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for bBevacizumab. The CRL did not identify any outstanding scientific issues on the dossier and informs the need for the completion of a pre-approval inspection of the bBevacizumab manufacturing facility.